Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer

Prashant Dogra¹,² • Javier Ruiz Ramírez¹ • Joseph D. Butner¹ • Maria J. Peláez¹ • Caroline Chung³ • Anupama Hooda-Nehra⁴,⁵ • Renata Pasqualini⁴,⁶ • Wadih Arap⁴,⁵ • Vittorio Cristini¹,⁷,⁸ • George A. Calin⁹ • Bulent Ozpolat¹⁰ • Zhihui Wang¹,²

Received: 19 October 2021 / Accepted: 21 January 2022 / Published online: 16 March 2022 © The Author(s) 2022

ABSTRACT

Purpose Downregulation of miRNA-22 in triple-negative breast cancer (TNBC) is associated with upregulation of eukaryotic elongation 2 factor kinase (eEF2K) protein, which regulates tumor growth, chemoresistance, and tumor immunosurveillance. Moreover, exogenous administration of miRNA-22, loaded in nanoparticles to prevent degradation and improve tumor delivery (termed miRNA-22 nanotherapy), to suppress eEF2K production has shown potential as an investigational therapeutic agent in vivo.

Methods To evaluate the translational potential of miRNA-22 nanotherapy, we developed a multiscale mechanistic model, calibrated to published in vivo data and extrapolated to the human scale, to describe and quantify the pharmacokinetics and pharmacodynamics of miRNA-22 in virtual patient populations.

Results Our analysis revealed the dose-response relationship, suggested optimal treatment frequency for miRNA-22 nanotherapy, and highlighted key determinants of therapy response, from which combination with immune checkpoint inhibitors was identified as a candidate strategy for improving treatment outcomes. More importantly, drug synergy was identified between miRNA-22 and standard-of-care drugs against TNBC, providing a basis for rational therapeutic combinations for improved response.

Conclusions The present study highlights the translational potential of miRNA-22 nanotherapy for TNBC in combination with standard-of-care drugs.

KEY WORDS allometry • cancer treatment • mathematical modeling • microRNA • pharmacokinetics and pharmacodynamics • precision medicine • tumor-immune interaction

INTRODUCTION

Triple-negative breast cancer (TNBC) accounts for up to 10–12% of all breast cancer cases, and has a 5-year survival that is 8–16% lower than the hormone-receptor positive (HR+) disease subtype (1). Mechanisms to overcome the aggressiveness, histopathological heterogeneity, and prevalence of TNBC in younger women represent major unmet needs in
contemporary cancer medicine (2). The severity of TNBC is further aggravated due to the lack of broadly-applicable targeted therapies, and by a high-rate of early metastases to the central nervous system and lungs (3). PARP inhibitors, such as olaparib and talazoparib, have been approved for TNBC with germline BRCA1 or BRCA2 gene mutations, but these are only reported in 15.4% of cases (4). Despite recent advances in developing therapeutics for treating TNBC such as immune checkpoint inhibitor immunotherapy (5), chemotherapy remains the most common recommended systemic regimens for TNBC, even though rapid development of chemorresistance is common (6).

An emerging body of evidence has supported key functional roles of microRNAs (miRNAs) in sustaining tumor proliferation, resisting growth inhibitors and cell death, inducing tumor invasion and metastasis, and promoting angiogenesis (7), suggesting that miRNAs may function as valuable oncologic therapy targets (8–10). Amongst the multitude of miRNAs, miRNA-22 (a chain of non-coding RNA consisting of 22 nucleotides) has been found to play a critical role in cancer initiation and progression processes (11, 12). Indeed, miRNA-22 has been extensively studied as a regulator of tumor suppressor genes like p53 (13) and as a repressor of the oncogene c-Myc (14) in many different cancers, including TNBC (12), hormone-dependent breast cancer (15), and colon cancer (16), and for its roles in metastasis suppression in breast cancer, ovarian cancer (17), and in the sensitization of esophageal carcinoma to γ-ray radiation (18).

miRNA-22 has been shown to be downregulated in TNBC, reducing inhibitory control over the eukaryotic elongation 2 factor kinase (eEF2K), a tumor growth-promoting and chemoresistance-inducing protein (12, 19). Importantly, eEF2K was also found to enhance the expression of PD-L1, and is thus implicated for its role in blocking tumor immunosurveillance (20). Inhibiting these tumorigenic effects of eEF2K via exogenous administration of miRNA-22 represents a potential therapeutic approach to improve the response of TNBC to chemotherapy and/or immunotherapy with immune checkpoint inhibitors. However, naked miRNA has a short half-life in plasma due to its vulnerability to ribonucleases, shows limited tumor penetration and cellular uptake due to its negative charge, and has off-target effects due to non-specific delivery (21). To overcome these shortcoming, nanoparticle (NP)-based drug delivery systems are being studied to improve the delivery of miRNAs to tumor cells (21). While the application of nanomaterials in cancer has been promising in improving tumor imaging and drug delivery (4, 22–27), challenges associated with low tumor deliverability due to off-target accumulation and limited tumor penetration continue to limit their clinical success (28). To this end, mechanistic mathematical modeling can be a valuable in-silico tool to help overcome this challenge, by furthering our understanding of NP-mediated miRNA-22 delivery in TNBC in vivo.

Mathematical modeling has been used to investigate the mechanisms relevant to tumor response to miRNA-based treatment. For instance, a system of ordinary differential equations (ODEs) with a delay term has been used to study feedback loops between the oncogenes Myc, EF2, and miRNA-17-92 (29). This model was subsequently expanded by integrating nine different mechanisms to evaluate how miRNAs regulate translation (30), and to study how the inactivation of a transcription factor is involved in cardiac dysfunction and cancer (31). In another notable study (32), an energy availability pathway involving miRNA-451 was analyzed in order to elucidate the difference between invasion and proliferation regimes in cancer cells, which was accomplished by combining a pair of ODEs governing the miRNA and glucose concentration with a system of partial differential equations (PDEs) employing transport mechanisms, such as diffusion, chemotaxis, and haptotaxis. Additionally, a signaling pathway relating miRNA-21, miRNA-155, and miRNA-205 to the proliferation and apoptosis of non-small-cell lung cancer cells has been examined with a series of modeling studies (33, 34). A noteworthy feature of the mathematical approach in (34) is the inclusion of a directional migration term, which takes into account the competition for available space between cells under the assumption of a logistic growth rate for cancer cells.

While previous modeling works focused on the molecular interactions of miRNAs associated with their therapeutic outcome, they lacked the inclusion of a viable drug delivery system and the related pharmacokinetics and drug delivery mechanisms required to assess the feasibility of miRNAs as a systemically-deliverable therapy for cancer. Therefore, to support the development of miRNA-22 as a viable therapy for TNBC, here we present a mechanistic mathematical model, formulated as a system of ODEs, to describe the tumoral transport of NPs, and the known molecular interactions of miRNA-22 with its associated oncogenes to predict TNBC growth. Our multiscale model incorporates processes pertinent to systemic NP pharmacokinetics, intratumoral transport of NPs, and the pharmacodynamics of miRNA-22 in the context of TNBC growth. Our multiscale model incorporates processes pertinent to systemic NP pharmacokinetics, intratumoral transport of NPs, and the known molecular interactions of miRNA-22 with its associated oncogenes to predict TNBC growth. Following model calibration with in vivo data that was then allometrically scaled to humans, we simulated clinically relevant treatment of TNBC with miRNA-22 to obtain the dose-response relationship at the individual and population scales, thus helping to reveal the optimal dose and frequency of treatment for each individual “virtual” patient. Local and global sensitivity analyses of key model parameters revealed the importance of molecular interactions, tumor vascularization, miRNA-22 potency, NP characteristics, and immune checkpoint effects of anti-PD-L1 in governing the outcome of miRNA-22 therapy, thus highlighting some of the key determinants of treatment outcome and suggesting the potential benefit of combination with immune checkpoint inhibitors. Drug synergy was identified to occur between miRNA-
22 and standard-of-care therapies (including both chemotherapy and immunotherapy) studied in this work. As a result, our mechanistic model may serve as a useful computational means to help design and optimize a therapeutic framework for future clinical trials of miRNA-22.

METHODS

Mathematical Model Development

We present a multiscale mechanistic model to simulate the in vivo and translational pharmacokinetics (PK) and pharmacodynamics (PD) of NP-mediated miRNA-22 therapy in TNBC, alone or in combination with chemotherapy or immunotherapy (here collectively referred to as agents), and thus investigate the factors governing the delivery of agents and their therapeutic efficacy. The model consists of two main compartments (Fig. 1), represented by the plasma and tumor, where the latter is sub-compartmentalized into vascular, interstitial, cellular membrane, and cytosolic space. After injection into the plasma compartment, agents are cleared through various physiological processes, which (along with the volume of distribution of agents) govern their systemic (i.e., plasma) pharmacokinetics. From the plasma compartment, bidirectional perfusion-mediated delivery characterizes the transport of agents into the tumor vasculature, from which the extravasation of agents across the permeable tumor vasculature introduces them into the tumor interstitium. Once in the interstitium, given the absence of advection due to high interstitial fluid pressure (35, 36), the agents undergo diffusion to reach the interstitium-cell membrane interface, and then specific biophysical processes occur to ensure delivery to the target site to invoke the pharmacodynamic effects of the agents, based on the type of agent. For instance, NPs undergo endocytosis into cancer cells where they release miRNA-22 in the cytosol, whereas free drugs simply diffuse into the cytosol and antibodies bind to their corresponding cell surface receptors (e.g. PD-L1 in the current context).

Following delivery of agents to the target site, the pharmacodynamic component of the model is then engaged such that miRNA-22 acts by inhibiting the production of eEF2K protein, leading to inhibition of tumor growth. Also, because there is growing evidence in the literature that eEF2K induces the production of PD-L1 (20), this pathway was incorporated in the model to explore the engagement of immune checkpoints by eEF2K for tumor survival. The reference chemotherapeutic (i.e., doxorubicin) acts by inducing apoptotic cell death, whereas anti-PD-L1 antibodies act by inhibiting the tumor protective effects of PD-L1. Note that the mechanism of action of anti-PD-L1 antibodies modeled here includes the degradation of PD-L1 protein. Simulations and analysis of the model will help to provide insights into the systemic and tumoral pharmacokinetics of therapeutic agents and NPs, along with the effects on tumor progression. We then use the model as an in-silico tool to simulate virtual clinical trials in order to explore the effects of patient variability and other system parameters on treatment outcomes with mono- or combination therapies.

The various transport and pharmacological processes described above and shown in Fig. 1 have been formulated into a system of ordinary differential equations (ODEs; Eqs. 1–17) to obtain the temporal evolution of model behaviors of interest, including tumor growth. Equations pertaining to various compartments and biological processes are described below:

Equation for NP mass kinetics in plasma (NP(t)):

\[
\frac{dN_P(t)}{dt} = \left( \frac{N_V(t)}{V_{BV}} - \frac{N_P(t)}{V_P} \right) \cdot Q(t) \cdot B(t) - k_{Cl} \cdot N_P(t),
\]

(1)

where \(N_V(t)\) is NP mass kinetics in tumor vasculature; \(V_{BV}\) (for \(t^*B(t)\)) and \(V_P\) are volumes of tumor vasculature and plasma compartments, respectively; \(f_s\) is the vascular volume fraction of the tumor; \(B(t)\) represents tumor volume; \(Q(t)\) represents plasma flow rate per unit volume of tumor; \(k_{Cl}\) represents systemic clearance of NPs; \(N_0\) is the injected dose of NPs; and \(i\) represents the injection times (in weeks) post inoculation of tumor in mice (\(i = 2, 3, 4, 5\)). Note that \(Q(t)\) (units, mL·mL⁻¹·wk⁻¹) obeys the following empirical relationship with tumor volume \(B(t)\): \(Q(t) = 2843e^{−0.65B(t)}\), obtained by fitting a monoexponential function to data from literature (37). Note that for human simulations, \(Q(t)\) was assumed to be 1512 mL·mL⁻¹·wk⁻¹ irrespective of tumor size (38). Given that tissue density is ~1 g/cm³ (39), tumor plasma flow rate is provided in the units of mL·mL⁻¹·wk⁻¹ in our work, which is numerically equivalent to mL·g⁻¹·wk⁻¹ as typically used in the literature. In addition, NP clearance in mice \(k_{Cl}\) (units, wk⁻¹) varies empirically with NP diameter (\(\phi_{NP}\) units, cm) as: \(k_{Cl} = 0.11e^{-0.01\phi_{NP}^{0.5}}\), obtained by fitting the plasma half-life data of quantum dots of varying sizes from the literature (40, 41). For human simulations, the value of \(k_{Cl}\) was allometrically scaled (see Allometric Scaling Section, below).

Equation for NP mass kinetics in tumor vasculature (\(N_V(t)\)):

\[
\frac{dN_V(t)}{dt} = \left( \frac{N_P(t)}{V_P} - \frac{N_V(t)}{V_{BV}} \right) \cdot Q(t) \cdot B(t) - P_{NP} \cdot S \cdot N_V(t), N_V(0) = 0
\]

(2)

where \(P_{NP}\) indicates NP permeability across tumor vasculature and \(S\) is the tumor vascular surface area per unit tumor volume (units, cm²/cm³). In vivo, \(S\) relates to tumor volume \(B(t)\) as \(S = 0.26e^{-4.5B(t)}+138e^{-0.04B(t)}\), obtained empirically from the literature (42), and \(P_{NP}\) (units, cm·wk⁻¹) is a function of tumor vascular porosity and the ratio of NP size (\(\phi_{NP}\) to

 Springer
tumor vascular pore size \( \phi_{\text{pore}} \), units, cm \(^3\) \(^{45}\). For human simulations, \( S \) was fixed at 135 cm\(^2\)/cm\(^3\) irrespective of tumor size \(^{42}\).

**Equation for NP mass kinetics in tumor interstitium \( (N_I(t)) \):**

\[
\frac{dN_I(t)}{dt} = P_N \cdot S \cdot N_I(t) - \frac{D_{NP}}{L^2} \cdot N_I(t), \quad N_I(0) = 0
\]  

where \( D_{NP} \) is the diffusivity of NPs in tumor interstitium \((0.0112 \text{ cm}^2/\text{cm}^3) \), and \( L \) is the characteristic interstitial distance between tumor vessels and cancerous cells, referred to herein as the intercapillary length in the tumor.

**Equation for NP mass kinetics in cancer cell membrane \( (N_M(t)) \):**

\[
\frac{dN_M(t)}{dt} = \frac{D_{NP}}{L} \cdot N_I(t) - k_{endo} \cdot N_M(t), \quad N_M(0) = 0
\]  

where \( k_{endo} \) (units, wk\(^{-1}\)) is the rate of endocytosis of NPs into tumor cells, and may be obtained by equating work done by the membrane motor proteins against surface tension of cell membrane \(^{44}\).

**Equation for NP mass kinetics in cancer cell cytosol \( (N_C(t)) \):**

\[
\frac{dN_C(t)}{dt} = k_{endo} \cdot N_M(t) - \delta_{NP} \cdot N_C(t), \quad N_C(0) = 0
\]  

where \( \delta_{NP} \) is NP degradation rate.

**Equation for miRNA concentration kinetics in cancer cell cytosol \( (C_M(t)) \):**

\[
\frac{dC_M(t)}{dt} = \frac{\delta_0 M_0}{1 + e^{B(t) - M_0}} - \delta_M C_M(t), \quad C_M(0) = \frac{\delta_0}{\delta_M}
\]  

where \( \delta_0 \) is the intrinsic production rate of miRNA-22 in the tumor cytosol; \( e_B \) is the efficiency of tumor on inhibiting miRNA-22 production; \( M_0 \) is the mass of miRNAs loaded in a single NP, which depletes over time due to the release of miRNAs from the NP at a rate \( \delta_{rel} \), as indicated by the closed-form solution \( (M_0 e^{-\delta_{rel} B(t)} - M(0) = M_0) \) of the ODE that describes the rate of change of mass of miRNA \( M \) inside a NP \( \frac{dM(t)}{dt} = -k_{rel} \cdot M, \quad M(0) = M_0 \); \( i \) represents the nanotherapy injection times (in weeks) post inoculation of tumor in mice \((i = 2, 3, 4, 5) \); and \( B(t) \) is the cytosolic volume of tumor \((= f_c \cdot f_B \cdot \text{cyt} \cdot B(t)) \), where \( f_c (\approx 0.4) \) is the cancer cell volume fraction of a tumor \(^{45}\) and \( f_B (\approx 0.4) \) is the cytoplasmic volume fraction of a cancer cell \(^{46}\). \( \delta_M \) is the degradation rate of miRNAs. Note that the initial condition \( C_M(0) \) is estimated at the trivial steady state of the system when \( B(t) = 0 \) and no exogenous administration of miRNAs has occurred, such that \( C_M(0) = \frac{\delta_0}{\delta_M} \).

**Equation for anti-PD-L1 antibody concentration kinetics in plasma \( (C_{Ab, i}(t)) \):**
Here, \( j \) represents the injection times (in weeks) post inoculation of tumor in mice defined in the set \( Q^J = \{1, 1.71, 2.43, 3.14, 3.86, 4.57\} \); \( \text{Dose}_{Ab} \) represents the dose of antibodies; \( k_{\text{abs}} \) is the absorption rate constant of antibodies from the peritoneum into plasma after intraperitoneal (IP) injection; \( V_{\text{pe}} \) is the volume of peritoneal fluid in female mice (0.1 mL) \((47)\); and \( C_l_{\text{Ab}} \) is the systemic clearance of antibodies. Note that in mouse experiments, antibodies were given IP; therefore, the initial plasma concentration of antibodies \( C_{0,\text{Ab}} \) is zero. However, for human simulations, immunotherapy was administered as an intravenous (IV) bolus injection, therefore the initial plasma concentration of antibodies \( C_{0,\text{Ab}} \) is non-zero and is calculated based on the initial dose (\( \text{Dose}_{\text{Ab}} \)) and systemic volume of distribution \( (V_{D,\text{Ab}}) \) of the given antibody. As a result, the first term of Eq. 7 that accounts for systemic absorption of the drug from the peritoneum is removed during simulations.

**Equation for anti-PD-L1 antibody concentration kinetics in tumor vasculature \((C_{\text{Ab, V}}(t))\):**

\[
\frac{dC_{\text{Ab, V}(t)}}{dt} = \frac{C_{\text{Ab, P}(t)} - C_{\text{Ab, V}(t)}}{V_{\text{B, V}}} \left[ Q(t) \cdot B(t) - P_{\text{Ab}} \cdot S \cdot C_{\text{Ab, V}(t)} \right] \Rightarrow C_{\text{Ab, V}(0)} = 0
\]

where \( P_{\text{Ab}} \) indicates antibody permeability across the tumor vasculature.

**Equation for anti-PD-L1 antibody concentration kinetics in tumor interstitium \((C_{\text{Ab, I}}(t))\):**

\[
\frac{dC_{\text{Ab, I}(t)}}{dt} = P_{\text{Ab}} \cdot S \cdot C_{\text{Ab, V}(t)} - D_{\text{Ab}} \cdot \frac{L^2}{C_{\text{Ab, I}}(t)} - C_{\text{Ab, I}(t)} \Rightarrow C_{\text{Ab, I}(0)} = 0
\]

where \( D_{\text{Ab}} \) is the diffusivity of antibodies in tumor interstitium \((0.0784 \text{ cm}^2 \text{ wk}^{-1})\).

**Equation for anti-PD-L1 antibody concentration kinetics in cancer cell membrane \((C_{\text{Ab, M}}(t))\):**

\[
\frac{dC_{\text{Ab, M}(t)}}{dt} = \frac{D_{\text{Ab}} \cdot L^2}{C_{\text{Ab, M}}(t)} - \delta_{\text{Ab}} \cdot C_{\text{Ab, M}(t)} \Rightarrow C_{\text{Ab, M}(0)} = 0
\]

where \( \delta_{\text{Ab}} \) is the degradation rate of antibodies.

**Equation for doxorubicin concentration in plasma \((C_{\text{D, P}}(t))\):**

\[
\frac{dC_{\text{D, P}(t)}}{dt} = \frac{(C_{\text{D, V}(t)} - C_{\text{D, P}(t)}) \cdot Q(t) \cdot B(t) - C_{\text{Dox}} \cdot C_{\text{D, P}(t)}}{V_{\text{P}}},
\]

\[
C_{\text{D, P}(t)} = \begin{cases} 0, & t = 0 \\ C_{\text{D, D}}, & t = i \end{cases}
\]

where \( C_{\text{Dox}} \) is the plasma clearance of doxorubicin; \( C_{\text{D, D}} \) is the initial concentration of doxorubicin calculated based on the injected dose of 4 mg/kg and the given volume of distribution \((\text{Table II})\); \( i \) represents the injection times (in weeks) post inoculation of tumor in mice \((i = 1, 2, 3)\).

**Equation for doxorubicin concentration in tumor vasculature \((C_{\text{D, V}}(t))\):**

\[
\frac{dC_{\text{D, V}(t)}}{dt} = \frac{(C_{\text{D, P}(t)} - C_{\text{D, V}(t)}) \cdot Q(t) \cdot B(t) + J \cdot S}{V_{\text{B, V}}},
\]

\[
C_{\text{D, V}(0)} = 0
\]

where \( J \) is the diffusive flux of doxorubicin across the tumor vasculature into tumor interstitium, and is given by \( J = -D_{\text{Dox}} \cdot \frac{(C_{\text{D, V}(t)} - C_{\text{D, I}(t)})}{\Delta x} \). Here, \( D_{\text{Dox}} \) is the diffusivity of doxorubicin in tumor interstitium \((0.4933 \text{ cm}^2 \text{ wk}^{-1})\) and \( \Delta x \) is the thickness of blood capillary wall \((5 \mu \text{m})\).
tumor cytosol; \( A_{E,P} \) is the stimulation factor of eEF2K effects on PD-L1 production; \( K_{E,P} \) is the Michaelis-Menten constant for eEF2K effects on PD-L1 production; \( \delta_P \) is the degradation rate of PD-L1 protein; \( A_{O,P} \) is the stimulation factor of anti-PD-L1 antibody effects on PD-L1 degradation; \( EC_{50}^{O} \) is the half-maximal effective concentration of anti-PD-L1 antibody for its effect on PD-L1 protein degradation; and \( C_P^o \) is the initial concentration of PD-L1 protein.

**Equation for tumor volume kinetics** (\( B(t) \)):

\[
\frac{dB(t)}{dt} = \sigma \left( \frac{A_{E,P} C_E(t) \left( \frac{1 - B(t)}{B^*} \right) \cdot B(t) - \delta_{B,t}}{1 + \varepsilon_P \cdot C_P(t)} \right).
\]

**Parameter Sensitivity Analysis**

To investigate the importance of various model parameters in causing tumor shrinkage in patients undergoing treatment with a weekly dose of 0.026 mg/kg miRNA-22 (loaded in NPs), we performed local (LSA) and global (GSA) sensitivity analyses (43, 62–66) by perturbing the parameters of interest (highlighted by a dagger in Tables I and II) over a range of 0.2× to 5× of their corresponding baseline values.

The model was solved numerically as an initial value problem in MATLAB R2018a by using the built-in function `ode15s`, and fit to the in vivo data from the literature (12, 56–58) by using the built-in function `lsqcurvefit`. Correlation analysis was then performed between model fits and experimental data to assess the goodness of fit.

**Allometric Scaling**

For human simulations, the rate constants \( k_{EC}, \sigma, \delta_{B,t}, \) and \( \delta_{B,C} \) were allometrically scaled from values determined for mice based on body weights and the standard allometric exponent for rate constants, i.e., \(-0.25 \) (59), such that the value of parameter \( i \) for humans (\( P_i^h \)) was:

\[
P_i^h = P_i^m \left( \frac{BW_i}{BW_m} \right)^{-0.25},
\]

where \( P_i^m \) is the value of parameter \( i \) for mice, and \( BW_i \) and \( BW_m \) are the body weights assumed for humans (70 kg) and mice (0.02 kg), respectively. We note that a different scaling exponent was used in the above formula for a subset of parameters, as based on published reports, these were: dose and clearance calculations (exponent = 0.75) and volume of distribution calculations (exponent = 1.0) (60, 61).

**Treatment Response Evaluation**

The model was used to study the effect of miRNA-22 nanotherapy, alone or in combination with doxorubicin and/or atezolizumab, in virtual patients. The effect of therapy on tumor shrinkage was quantified by a metric defined as percent tumor growth inhibition (%TGI), such that \( \%\text{TGI} = \left( 1 - \frac{B_{\text{treated}}}{B_{\text{control}}} \right) \times 100 \), where \( B_{\text{treated}} \) and \( B_{\text{control}} \) represent treatment and control tumor volumes at the end of 104 weeks post tumor inception with a single cell. Note that, in the treatment scenario, therapy was initiated at 80 weeks post tumor inception, such that treatment was given over 24 weeks (~6 months). To evaluate tumor response at a population level, we employed a scale analogous to RECIST 1.1 (56), such that treatment response was classified as progressive disease (TGI ≤ 0%), stable disease (0% < TGI ≤ 30%), intermediate response (10% < TGI ≤ 50%), partial response (30% < TGI ≤ 50%), and major response (TGI > 50%).
Table 1  List of Biological Parameters and Initial Conditions

| Parameter Descriptions                                      | Units | Value            | Ref. |
|-------------------------------------------------------------|-------|------------------|------|
| **eEF2K-related parameters**                                |       |                  |      |
| $A_{B, E}$                                                  |       |                  |      |
| Stimulation factor for tumor effects on eEF2K production    |       | 11.9             | Est  |
| $A_{M, E}$                                                  |       |                  |      |
| Stimulation factor for miRNA-22 effects on eEF2K degradation|       | 10.52            | Est  |
| $K_{B, E}$                                                  | cm$^3$| 16.03            | Est  |
| $\delta_E$                                                  | wk$^{-1}$| 60.48      | (34) |
| $g_0^E$                                                     | wk$^{-1}$| 36.3           | Est  |
| $C_0^E$                                                     |       | 0.58             | Est  |
| **PD-L1-related parameters**                                |       |                  |      |
| $A_{E, P}$                                                  |       |                  |      |
| Stimulation factor for eEF2K effects on PD-L1 production    |       | 3.32             | Est  |
| $A_{Ab, P}$                                                 |       |                  |      |
| Stimulation factor for anti-PD-L1 antibody effects on PD-L1|       | 1.79             | Est  |
| $K_{E, P}$                                                  |       |                  |      |
| Michaelis-Menten constant for eEF2K effects on PD-L1       |       | 8.1              | Est  |
| $\delta_P$                                                  | wk$^{-1}$| 60.48      | (34) |
| $g_0^P$                                                     | wk$^{-1}$| 10.44         | Est  |
| $C_0^P$                                                     |       | 0.21             | Est  |
| **Tumor-related parameters**                                |       |                  |      |
| $A_{E, B}$                                                  |       |                  |      |
| Stimulation factor for eEF2K effects on tumor growth        |       | 4.5              | Est  |
| $K_{E, B}$                                                  |       |                  |      |
| Michaelis-Menten constant for eEF2K effects on tumor growth|       | 8.78             | Est  |
| $A_{E, D}$                                                  |       |                  |      |
| Stimulation factor for eEF2K effects on inducing chemoresistance |   | 0.1              | Est  |
| $K_{E, D}$                                                  |       |                  |      |
| Michaelis-Menten constant for eEF2K effects on inducing   |       |                  |      |
| chemoresistance                                             |       |                  |      |
| $\sigma^*$                                                  | wk$^{-1}$| 3.1 (miRNA-22, M)| Est  |
|                                                             |       | 3.75 (Dox, M)   |      |
|                                                             |       | 3.13 (Atezo, M) |      |
|                                                             |       | 0.43 (H)        |      |
| $B^*$                                                       | cm$^3$| 2.21 (miRNA-22, M)| Est  |
|                                                             |       | 2.5 (Dox, M)    |      |
|                                                             |       | 2.99 (Atezo, M) |      |
|                                                             |       | 100 (H)         |      |
| $\delta_{B, I}$                                             | wk$^{-1}$| 3.0 (M), 0.39 (H)| Est  |
| $\epsilon_P$                                               |       |                  |      |
| Efficiency of PD-L1 to inhibit immune-induced tumor death   |       | 1.9              | Est  |
| $\delta_{B, C}$                                             | wk$^{-1}$| 2.46 (M), 0.3198 (H)| Est  |
| $\phi_p$                                                   | nm    | 1700             | (67) |
| $L$                                                         | cm    | 0.01             | (68) |
| $\eta_{B, B}$                                               | cP    | 7.42             | (42) |
| $\eta_{B, I}$                                               | cP    | 3.5              | (69) |
| $S_D$                                                       | cm$^3$| 0.001            | (12) |
| $f_v$                                                      |       | 0.17             | (42) |
| $Q(t)^*$                                                   | mL mL$^{-1}$ wk$^{-1}$|                |      |
| $S$                                                         | cm$^2$cm$^{-3}$ | 308.6±5.8 (M), 135 (H) | (42) |

Mice and human specific parameters are specified by M and H in parantheses, respectively. Not specified in case of common values. $^*$ Dagger indicates patient-specific parameters perturbed for virtual clinical trial simulations. Abbreviations: Est- estimated via regression, Allo- allometrically scaled, Dox- doxorubicin, Atezo- atezolizumab.
Determination of Drug Synergy

The Chou-Talalay method (71) was used to identify drug synergy between miRNA-22 and its combination with standard-of-care drugs for TNBC (doxorubicin and/or atezolizumab). Occurrence of drug synergy allows the possibility of using a lower dose of the constituent drugs, which can reduce their adverse effects. The method involves determination of combination index (CI), such that CI < 1 is an indicator of existence of drug synergism. To calculate CI, the open source software COMPUSYN (available at https://www.combosyn.com/) was used to generate the analysis report, which has been provided in the Supplementary Information.

RESULTS AND DISCUSSION

Model Development, Calibration, and Baseline Solution

The multiscale mechanistic model developed to study the PK-PD of NP-mediated miRNA-22 therapy in TNBC, along with other clinically approved treatment modalities, was formulated as a system of ODEs (Eqs. 1–17) and solved numerically as an initial value problem. Some model parameters were known a priori (Tables I and II), while the rest were estimated through non-linear least squares fitting of the model to published in vivo datasets. The selected datasets include longitudinal measurements of tumor volume in mice bearing MDA-MB-231 xenografts under control conditions, or under treatment with one of the following therapies: 0.15 mg/kg (equivalent 4 μg/mouse) IV miRNA-22-loaded NPs once a week (12), 4 mg/kg IV doxorubicin once a week (56), and 5 mg/kg IP anti-PD-L1 immunotherapy (atezolizumab) once every 5 days (58).

We used the model to simulate the treatment protocols shown in Fig. 2, and the numerical solutions of tumor volume kinetics were then fit simultaneously to the four datasets to estimate the unknown model parameters (given in Tables I and II). Additionally, the model solution for eEF2K protein kinetics from the miRNA-22 simulation was fit to the available data (Fig. 2a). Model fits were in good agreement with the experimental data, as indicated by a strong Pearson

\[ e_{\text{EF2K}} \]
correlation (Fig. S1; $R > 0.96$, $P < 0.0001$). While the various experimental studies used above demonstrated the effects of individual therapies on TNBC progression, the model revealed additional insights into drug (and also NP) pharmacokinetics and molecular interaction dynamics leading to tumor response to the three therapies.

Fig. 2 Model calibration. Numerical solution of model fit to published in vivo data for treatment of MDA-MB-231 tumor-bearing mice with (a) NP-delivered miRNA-22, (b) doxorubicin, and (c) atezolizumab. Markers represent experimental data. Pearson correlation analysis results goodness of fit of the model are reported in Fig. S1.
As shown in Fig. 2a, simulated NP-mediated miRNA-22 therapy involved periodic IV administration of miRNA-22-loaded NPs into the plasma compartment, from where the NPs were cleared in a size-dependent fashion characterized by $k_Q$, and also transported to the tumor vascular sub-compartment in a perfusion-dependent manner governed by the plasma flow rate $Q$. Extravasation of NPs across the leaky tumor vasculature into the tumor interstitium, determined by the vascular permeability-surface area product $(P_S \cdot S)$, was followed by NP size-dependent diffusion through the tumor interstitium. Remaining NPs were ultimately endocytosed into the tumor cytosolic sub-compartment (i.e., cancer cell cytosol), followed by NP degradation and release of miRNA-22 into the cancer cell cytosol. As a result, miRNA-22-induced inhibition of eEF2K production was observed relative to the control case, which reduced the downstream production of cancer cell transmembrane protein PD-L1. The overall effect of miRNA-22 therapy on alterations in protein expression manifested as tumor growth inhibition mediated by suppressed induction of tumor growth by eEF2K and increased vulnerability to tumor immunogenicity due to depletion of the immune checkpoint PD-L1.

To explore the therapeutic combinations of miRNA-22 with FDA approved chemotherapies and immunotherapies, we calibrated the model with in vivo data from treatment of TNBC with doxorubicin (Fig. 2b) and atezolizumab (Fig. 2c). In response to doxorubicin therapy (Fig. 2b), the model showed reduction in tumor growth relative to the control case due to drug concentration-dependent increase in tumor death rate $\delta_B$. This is accompanied by reduced expression levels of eEF2K and PD-L1, but increased basal miRNA-22 expression level. Note that tumor growth has an inhibitory effect on miRNA-22 production (12), but stimulates eEF2K production, which tends to stimulate tumor growth in a complimentary feedback process (12, 19). We next modeled the effect of anti-PD-L1 immunotherapy (atezolizumab) in a simplistic fashion by targeting PD-L1 degradation rate $\delta_P$, such that atezolizumab enhances the degradation of PD-L1 in a drug concentration-dependent manner. As a result, as shown in Fig. 2c, due to depletion of PD-L1, there is inhibition of tumor growth compared to the control. The parameters estimated as a result of the above model calibrations are given in Tables I and II.

**Model Extrapolation to Human Scale**

To study the translational value of miRNA-22 and associated potential combination therapies, we extrapolated the in vivo mechanistic model to human scale, either by substituting known physiological parameters with human values, or by allometric scaling of unknown parameters from mice to humans (see Allometric Scaling in Methods). In Fig. 3a, a representative simulation of NP-mediated miRNA-22 therapy in a virtual adult patient (body weight 70 kg) is shown following once a week (QW) IV administration of 0.026 mg/kg miRNA-22 (allometrically scaled dose) for six months, starting 80 weeks after the inception of tumor with a single cell. As shown, eEF2K and PD-L1 levels are suppressed throughout the duration of treatment, thereby leading to ~29% TGI compared to the control case. The parameters used for the representative simulation are the baseline values shown in Tables I and II.

**Dose-Response Relationship and Population Variability**

To investigate the effect of changes in miRNA-22 dosage and treatment frequency on %TGI, dose-response curves (DRCs) was generated for a representative individual by simulating treatment with miRNA-22 nanotherapy at different doses (0–0.2 mg/kg), either once weekly (QW) or once every two weeks (Q2W) (Fig. 3b). DRCs were also generated for slow, medium, and fast growing tumors at the two treatment frequencies. Note that the ratio of tumor immunogenicity-induced death rate (e.g., tumor death rate due to normal immune effects without drug intervention) to tumor growth rate $\delta_B/\sigma$ indicates how fast a tumor grows; e.g., within the scope of this work, the ratios of 0.99, 0.9, and 0.75 indicate slow, medium, and fast growing tumors, respectively (Fig. S3). As shown in Fig. 3b, therapeutic response tends to saturate around a dose of 0.05 mg/kg in these six scenarios, and even beyond 0.026 mg/kg (dose obtained through allometric scaling; see Allometric Scaling in Methods), tumors do not exhibit significant increase in %TGI, hence 0.026 mg/kg was chosen as the reference dose in humans for further investigation. As for the slow growing tumors, they show a much higher response to therapy (~two-fold) than their rapidly proliferating counterparts. Additionally, irrespective of the rate of tumor growth, the QW protocol causes greater %TGI than Q2W.

Further, by creating a virtual population of 2000 patients through LHS of patient-specific parameters between ±50% of their baseline values, the effects of inter-individual variability on %TGI for different doses of QW miRNA-22 were investigated and presented in a manner analogous to the RECIST 1.1 classification (59, 72). As shown in Figs. 3c and S2, the patient population showed significant improvement in response with increasing dose up to ~0.02 mg/kg, such that stable disease (0% < TGI ≤ 10%) cases dropped exponentially, and the population of intermediate responders (10% < TGI ≤ 30%) and major responders (> 50% TGI) grew rapidly. Also, a steady increase was observed in the population of partial responders (30% < TGI ≤ 50%). However, beyond ~0.02 mg/kg dose, the population of major responders quickly saturated at a value of ~20%, while the population of partial responders increased with increasing drug dose up to ~0.1 mg/kg, eventually settling at ~25%; the remaining population (~55%) primarily consisted of intermediate
responser. Thus, these observations support our use of the allometrically calculated dose of 0.026 mg/kg; this was used as the reference value for further analysis. Note that progressive disease (≤0% TGI) was only seen in the no treatment scenario; this indicates that treated tumors do not grow beyond the size of the corresponding control tumors, and hence as per our definition of %TGI, ≤0% values are not observed under treatment. These simulations provide quantification of the variation in treatment response that can be expected from physiological variability and tumor heterogeneity on a population scale, and can thus support treatment personalization to maximize patient benefit. Note that the parameters used to generate the virtual population are marked by a dagger in Tables I and II.

**Parameter Sensitivity Analysis**

For a more complete understanding of the effects of both patient-specific and treatment-related parameters on %TGI following 0.026 mg/kg QW dose of miRNA-22 nanotherapy starting 80 weeks post initiation of tumor and delivered for six months, we performed local (LSA) and global (GSA) sensitivity analyses by perturbing parameters over a range of 0.2× to 5× of the baseline values (43). As shown in Fig. 4a, GSA ranked the 21 model parameters into eight categories based on their sensitivity indices (by using one-way ANOVA and Tukey’s test), out of which we discuss the top five ranking parameter brackets below.

First, as shown in Fig. 4a, miRNA-22 degradation rate ($\delta_{M}$) stands out for its influence on %TGI, indicating that the stability of the miRNA is critical to ensure therapeutic efficacy, and an increase in degradation rate of miRNA-22 causes reduction in %TGI (as revealed by LSA, Fig. 4b), thereby reinforcing the need for NP-mediated delivery to protect the cargo until delivered to the cytosol. In the second bracket, we find tumor-specific parameters controlling PD-L1 and eEF2K protein production ($g^0_{P}$ and $g^0_{E}$, respectively), and the efficiency of PD-L1 ($\varepsilon_{P}$) at inhibiting immune cell-induced tumor death, suggesting that PD-L1-mediated tumor immunosurveillance blockade, eEF2K-induced tumor proliferation, and PD-L1 production that affect the intrinsic tumor growth and death are important determinants of miRNA-22 efficacy. This result suggests that delivering anti-PD-L1 therapies that target high PD-L1 activity can improve treatment outcomes when used in combination with miRNA-22.

---

Fig. 3 Translational PK-PD of miRNA-22. (a) Human extrapolation of in vivo mechanistic model simulating treatment with once weekly dose of miRNA-22 for six months. TGI indicates percent tumor growth inhibition. (b) Dose response curves of a virtual patient under scenarios of once weekly (QW) or once every two weeks (Q2W) dose of miRNA-22 for slow and fast growing tumors. (c) Effects of inter-individual variability on miRNA-22 therapy outcome for different QW doses, presented on a scale analogous to RECIST 1.1. Black arrow on x-axis indicates the dose of 0.026 mg/kg used for further analysis.
These parameters are followed by NP size ($\phi_{NP}$) and NP degradability ($\delta_{NP}$). NP characteristics strongly influence the systemic pharmacokinetics of NPs (driven by hepatic and renal clearance [43, 70, 73–75]) and also NP transport to and accumulation within the tumor (driven by extravasation across tumor vasculature, diffusion through tumor interstitium, endocytosis into cancer cells, and metabolism-dependent degradation in the cancer cell cytosol [4, 22]). These NP-specific parameters rank highly for their influence on %TGI due to their role in miRNA-22 delivery to the tumor. Of note, for the individual effects of NP size ($\phi_{NP}$), we observed an inverse monotonic trend between %TGI and the investigated parameter values, suggesting that an increase in NP size leads to reduced %TGI (Fig. 4b). This suggests that while smaller NPs have smaller drug loading capacity, this may be compensated by using larger quantities to deliver the same dose of drug, which can then outperform larger NPs primarily due to better pharmacokinetics and greater tumor penetration. Note that the corresponding number of NPs injected to deliver 0.026 mg/kg miRNA-22 via NPs of different sizes in our study ranged from ~90 billion (i.e., ~9 × 10^{10} for size 350 nm) to ~1.5 quadrillion (i.e., ~1.5 × 10^{15} for size 14 nm), which lies well within the range of values used in preclinical studies and clinical trials [76]. While we did not investigate renally clearable NPs (<10 nm) due to lack of reported clinical application for drug delivery, we anticipate poorer performance from such particles, primarily due to their short circulation half-life driven by rapid renal clearance [43, 77]. Further, within the same ranking bracket is the parameter governing the induction of eEF2K degradation by miRNA-22 ($A_{M,E}$), suggesting the expected significance of miRNA-22 for eEF2K degradation to inhibit tumor growth.

Parameters in the 4th and 5th ranking brackets include those that control the positive feedback between eEF2K protein and tumor growth ($A_{E,B}$, $A_{B,E}$), the half-maximal effective concentration of miRNA-22 in suppressing eEF2K ($EC_{50}^M$),
the potency of eEF2K in inducing tumor growth ($k_E$, $b$), and importantly, the tumor microvascular surface area ($S$). This suggests that the positive feedback role of eEF2K with tumor growth is secondary relative to its role in immune suppression (these effects are found in the second bracket), that the primary effective mechanism of action of miRNA-22 is immune suppression, and that associated reduction of tumor growth represents a beneficial – but secondary – therapeutic mechanism. The importance of tumor microvascular surface area is attributed to its role in determining rate of extravasation of NPs across tumor vasculature for drug delivery to the cells. However, tumor blood flow rate ($Q/f$) does not appear to have a significant impact on therapy efficacy. Together, our simulations find that tumor response is most sensitive to the immune checkpoint effects of PD-L1, miRNA-22-eEF2K interaction, miRNA-22 potency and stability, and NP characteristics. This finding may provide opportunities for patient-specific optimization of NP-mediated miRNA-22 therapy. It also warrants the use of combination therapies, particularly immune checkpoint inhibitors in combination with chemotherapeutics due to the chemoresistant influence of eEF2K, in order to achieve a better treatment outcome. In light of the ranking obtained through GSA, we understand that LSA may not be required to obtain a ranked order of parameters for their influence on %TGI, because unlike GSA, LSA does not incorporate the interactions between parameters that may influence the outcome, and thus only provides a limited assessment into the sensitivity of parameters. However, LSA can still be used to obtain the empirical relationships between individual parameters and model output, as shown in Fig. 4b.

**Combination Therapies, Population Variability, and Synergy**

We then sought to test the effects of combining miRNA-22 with standard-of-care drugs for TNBC, i.e., chemotherapeutics (doxorubicin) and immune checkpoint inhibitors (atezolizumab), for improvement in %TGI outcome. For these numerical experiments, clinically relevant doses of 2.4 mg/kg Q3W (once every three weeks) doxorubicin and 2 mg/kg Q3W atezolizumab were simulated for the representative virtual patient (shown in Fig. 3a) in various combinations with 0.026 mg/kg QW miRNA-22 given for six months, starting 80 weeks after tumor initiation. As shown in Fig. 5a, combining miRNA-22 nanotherapy with the immune checkpoint inhibitor improves the outcome from intermediate response to partial response (30% < TGI ≤ 50%), and combined with doxorubicin it leads to major response (TGI > 50%), which almost reaches complete response when the three modalities are given together. Further, to assess the effects of patient variability and tumor heterogeneity on drug combination outcomes, 2000 virtual patients were generated as before, and as shown in Fig. 5b, the three drug combination cases produced major response in ~60% of patients, which is about three times as many patients that showed major response with QW miRNA-22 monotherapy (Fig. 3c). However, response was reduced when miRNA-22 was given Q2W, either alone or in combination (Fig. 5c).

Finally, our observation that monotherapies without miRNA-22 show stable disease under the examined monotherapy treatment protocols (Fig. 5a), while two or three drug combinations with miRNA-22 produce significant improvements in treatment outcome, warrants testing for the occurrence of drug synergy between miRNA-22 and other drugs. For this, as shown in Fig. 6a, %TGI was calculated through model simulations for various doses of three monotherapies (miRNA-22 QW, doxorubicin Q3W, atezolizumab Q3W) and three combination therapies (miRNA-22 QW + doxorubicin Q3W, miRNA-22 QW + atezolizumab Q3W, miRNA-22 QW + doxorubicin Q3W + atezolizumab Q3W), and was used as an input for the Chou-Talalay method (71) to calculate the combination indices (CI) of drug combinations. As shown in Fig. 6b, CI values <1 for the three combinations of miRNA-22 indicate drug synergy with doxorubicin, atezolizumab, and doxorubicin+atezolizumab.

**CONCLUSIONS**

By using a multiscale mechanistic modeling approach, we studied the translational PK-PD of NP-loaded miRNA-22 as a therapeutic for TNBC, alone or in combination with other FDA approved therapeutics. For this, the model was first calibrated with published in vivo data involving treatment of MDA-MB-231 tumor-bearing mice with miRNA-22, doxorubicin, or an immune checkpoint inhibitor. The calibrated model was extrapolated to the human scale by substituting the physiological parameter values of mice with human’s, or by scaling of the parameters with standard allometric techniques. By using the extrapolated model, the dose-response curves and effects of inter-individual variability on treatment outcome were assessed and quantified through a scale analogous to RECIST 1.1. Percent tumor growth inhibition (%TGI) saturated at a dose of 0.05 mg/kg, irrespective of the treatment frequency and doubling time of the tumor. For our translational analysis, a dose of 0.026 mg/kg was used, obtained through allometric scaling of dose for mice. By creating a virtual patient population through perturbation of patient-specific parameters, patient response to variable miRNA doses was quantified, and it was observed that at 0.02 mg/kg, the fraction of patient population showing major response ($\geq 50\%$ TGI) to therapy saturated at ~40%. Within the scope of our computational investigation, further increment in the dose only increased the fraction of partial responders (i.e., patients exhibiting $\geq 30\%$ and < 50% TGI),
and appeared to saturate at 0.14 mg/kg, with ~35% patients exhibiting <30% TGI above that dose.

Parameter sensitivity analysis was conducted to identify the key determinants of %TGI in miRNA-22 nanotherapy. This analysis revealed the significance of miRNA-22-eEF2K interaction, eEF2K-tumor growth feedback loop, tumor vascularization, miRNA-22 potency and stability, NP characteristics, and also the immune checkpoint effects of PD-L1, which highlights the potential of miRNA-22 used in combination with anti-PD-L1 therapy to improve %TGI. This was supported by numerical experiments involving the combination of NP-loaded miRNA-22 with a clinically used immune

![Fig. 5](image)

**Fig. 5** Combination therapies. (a) Effects of QW dose of miRNA-22 (M) alone or in combination with doxorubicin (Dox or D), or atezolizumab (Atezo or A) on %TGI are show. b,c) Effects of inter-individual variability on %TGI following treatment with combination therapies is shown when miRNA-22 is given (b) QW or (c) Q2W. Note that the other three drugs were administered once every three weeks (Q3W) in all cases.

![Fig. 6](image)

**Fig. 6** Drug synergism. (a) Dose-response data generated from model simulations for various monotherapies and combination therapies. Note: Dox indicates doxorubicin and Ate represents atezolizumab. (b) Combination indices calculated with the Chou-Talalay method identify drug synergy for various combinations of miRNA-22. CI < 1 indicates drug synergism.
checkpoint inhibitor (atezolizumab) and/or doxorubicin. The triple combination of miRNA-22 with doxorubicin and this immune checkpoint inhibitor led to almost three-fold increase in population fraction exhibiting major response in comparison to miRNA-22 alone. Importantly, the suspected drug synergy between miRNA-22 and doxorubicin and immune-checkpoint inhibitors was confirmed through the Chou-Talalay combination, where indices were found to be <1.

Our analysis, based on a well-calibrated mathematical model extrapolated to the human scale, provides valuable pre-translational, quantitative insights into the limitations, challenges, and opportunities associated with the translation of miRNA-22 nanotherapy for TNBC patients. The ability of the model to explore the effects of patient variability and tumor heterogeneity through parameter perturbation and sampling demonstrates the utility of our in-silico tool to conduct virtual clinical trials to assess the effects of anticancer therapeutic agents, which can provide immediate feedback to biologists and clinicians regarding potential problems and their solutions to support the preclinical development and clinical translation of novel therapeutics. The model presented here captures the key processes involved in systemic pharmacokinetics of NPs; however, for a more detailed characterization, we will integrate the tumor compartment with a whole-body physiologically-based pharmacokinetic model in the future. Also, spatial tumor heterogeneity, genetic variability, and a more complete tumor microenvironment (with emphasis on immune cells) will be introduced in the tumor compartment of the model to further explore the effects of heterogeneity in drug diffusion barriers, drug resistant cell populations, and tumor immunosurveillance. Notably, other NP physicochemical attributes (e.g., surface charge, shape, surface coating) that are known to play a role in the pharmacokinetics of NPs will also be considered for their effect on miRNA-22 efficacy by incorporating machine learning-based correlations between NP properties and their hepato-splenic clearance or tumor vascular permeability. Lastly, while allometric scaling cannot replace clinical trials, it is commonly used in standard and experimental pharmaceutical research to support go/no-go decisions about clinical studies and calculate first-in-human dose of drugs. Therefore, while our model predictions are not as yet validated against clinical data, this work represents a meaningful step to support translational studies of miRNA-22 nanotherapy.

**SUPPLEMENTARY INFORMATION**

The online version contains supplementary material available at https://doi.org/10.1007/s11095-022-03176-3.

**ACKNOWLEDGMENTS AND DISCLOSURES**

The research work was supported by the National Science Foundation grant DMS-1930583 (VC, ZW), National Institutes of Health grants 1R01CA253865 (VC, BO, ZW), 1U01CA196403 (VC, ZW), 1U01CA1213759 (VC, BO, ZW), 1R01CA226537 (RP, WA, VC, ZW), 1R01CA222007 (VC, GAC, BO, ZW), U54CA210181 (VC), and the Cockrell Foundation (PD). GAC also acknowledges the Felix L. Haas Endowed Professorship in Basic Science, and the following grant support: NCI (1R01 CA182905-01, 1R01CA222007-01A1), NIGMS (1R01GM122775-01), DoD (Idea Award W81XWH2110030), a Team DOD grant in Gastric Cancer, a Chronic Lymphocytic Leukemia Moonshot Flagship project, a CILL Global Research Foundation 2019 grant, a CILL Global Research Foundation 2020 grant, a Mathers Foundation grant, an Institutional Research and Development Grant associated with the Brain SPORE 2P50CA127001. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests. GAC is the scientific founder of Ithax Pharmaceuticals. WA and RP are founders and equity stockholders of PhageNova Bio. RP is a paid consultant for PhageNova Bio and serves as its Chief Scientific Officer. RP and WA are also founders and stockholders of MBrace Therapeutics; RP serves as Chief Scientific Officer and a Board Member and WA is a member of the Scientific Advisory Board. None of these commercial relationships are related to the scope of the work presented in this manuscript.

**AUTHOR CONTRIBUTIONS**

ZW conceived the study and conceptualized the idea. PD, ZW designed the model and the model analysis. PD, JRR developed the model. PD performed the model analysis. PD, JRR, JDB, MJP, GAC, BO collected the data. PD, JRR, JDB, MJP, CC, AHN, RP, WA, VC, GAC, BO, ZW interpreted the results. PD, JRR, JDB, MJP, CC, AHN, RP, WA, VC, GAC, BO, ZW wrote or edited the manuscript.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission
directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Howard FM, Olopade OL. Epidemiology of triple-negative breast
cancer: a review. Cancer J. 2021;27(1):9–16.
2. Bianchinii G, Ballo JM, Mayer IA, Sanders ME, Gianni L. Triple-
negative breast cancer: challenges and opportunities of a heteroge-
neous disease. Nat Rev Clin Oncol. 2016;13(11):674–90.
3. Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-
negative breast cancer: treatment challenges and solutions. Breast
Cancer (Dove Medical Press). 2016;8:93–107.
4. Goel S, Ferreira CA, Dogra P, Yu B, Kutyreff CJ, Siamof CM,
Engle JW, BARNHART TE, Cristini V, Wang Z, Cai W. Size-
optimized ultrasmall porous silica nanoparticles depict vascularization-based differential targeting in triple negative breast
cancer. Small. 2019;15(46):e1903747.
5. Hecke AL, Tan AR. Checkpoint inhibitor therapy for metastatic
triple-negative breast cancer. Cancer Metastasis Rev. 2021;40(2):
537–47.
6. Goncalves H Jr, Guerra MR, Duarte Cintra JR, Fayer VA, Brum
IV, Bastamanate Teixeira MT. Survival study of triple-negative and
non-triple-negative breast cancer in a brazilian cohort. Clin Med
Insights Oncol. 2018;12:1179554918790653.
7. Garzon R, Calin GA, Croce CM. Microrna in cancer. Annu Rev
Med. 2009;60:167–79.
8. Bader AG, Brown D, Winker M. The promise of microrna re-
placement therapy. Cancer Res. 2010;70(18):7027–30.
9. Ross J. New hope for a microrna therapy for liver cancer. Cell.
2009;137(6):990–2.
10. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C,
Svoronos A, Braddock DT, GLazer PM, Engelman DM, Saltznan WM, Slack FJ. Microrna silencing for cancer therapy
targeted to the tumour microenvironment. Nature. 2015;518(7537):107–10.
11. Calin GA, Croce CM. Microrna-cancer connection: the beginning
of a new tale. Cancer Res. 200666(15):7390–4.
12. Gorur A, Bayraktar K, Ivan C, Mokhilis HA, Bayraktar E,
Kahraman N, Karakas D, Karanil S, Kabil NN, Kanlikiker P,
Adan B, Tamer I, Wang Z, Cristini V, Lopez-Berestein G, Calin
G, Ozpolat B. Ncrna therapy with mirna-22-3p suppresses the
growth of triple-negative breast cancer. Mol Ther Nucleic Acids.
2021;23:930–43.
13. Tsuchiya N, Izumiya M, Ogata-Kawata H, Okamoto K, Fujiwara
Y, Nakai M, Okabe A, Schetter AJ, Bowman ED, Midorikawa Y,
Sugiyama Y, Aburatani H, Harris CC, Nakagama H. Tumor sup-
pressor mir-22 determines p53-dependent cellular fate through
post-transcriptional regulation of p21. Cancer Res. 2011;71(13):
4628–39.
14. Xuong J, Du Q, Liang Z. Tumor-suppressive microrna-22 inhibits
the transcription of c-box-containing c-myc target genes by silencing
c-myc binding protein. Oncogene. 2010;29(35):4080–8.
15. Xuong J, Yu D, Wei N, Hu H, Cai T, Huang Y, Wu C, Zheng X, du
Q, Liu D, Liang Z. An estrogen receptor alpha suppressor, mirna-
22, is downregulated in estrogen receptor alpha-positive human
breast cancer cell lines and clinical samples. FEBS J. 2010;277(7):
1681–94.
16. Alvarez-Diaz S, Valle N, Ferrer-Mayorga G, Lombardia L,
HERRERA M, Dominguex O, et al. Microrna-22 is induced by vita-
min d and contributes to its antiproliferative, antimigratory and
gene regulatory effects in colon cancer cells. Hum Mol Genet.
2012;21(10):2157–65.
17. Patel JB, Appiah BN, Burnett RM, Bhat-Nakshatri P, Wang G,
Mehta R, Badve S, Thomson MJ, Hammond S, Steeg P, Liu Y,
Nakshatri H. Control of c-cbl oncogene expression in metastatic
breast cancer cells through microrna miR-22. Oncogene. 2011;30(11):
1290–301.
18. Wang XC, Zhang ZB, Wang YY, Wu HY, Li DG, Meng AM, Fan
FY. Increased mirna-22 expression sensitizes esophageal squamous
cell carcinoma to irradiation. J Radiat Res. 2013;54(5):401–8.
19. Wang X, Xie J, Proud CG. Eukaryotic elongation factor 2 kinase
(eef2k) in cancer. Cancers. 2017;9(2):162.
20. Wu Y, Xie J, Lin X, Lenzhine RV, Wang X, Fang DM, Nasser ZD,
Butler LM, Li J, Proud CG. Eef2k enhances expression of pd-h1 by
promoting the translation of its mrna. Biochem J. 2020;477(22):
4367–81.
21. Lee SWL, Paoletti C, Campisi M, Osaiki T, Adriani G, Kamm RD,
MATTU C, Chiono V. Microrna delivery through nanoparticles, J
Control Release. 2019;313:80–95.
22. Goel S, Zhang G, Dogra P, Nizzero S, Cristini V, Wang Z, et al.
Sequential deconstruction of composite drug transport in metastatic
breast cancer. Sci Adv. 2020;6(26):eaba4498.
23. Brachi G, Ruiz-Ramirez J, Dogra P, Wang Z, Cristini V, Giardelli
G, et al. Intratumoral injection of hydrogel-embedded nanoparticles
enhances retention in glioblastoma. Nanoscale. 2020;12(46):
23838–50.
24. Hosoya H, Dobroff AS, Driessen WH, Cristini V, Brinker LM,
Staquicini FI, et al. Integrated nanotechnology platform for
tumor-targeted multimodal imaging and therapeutic cargo release.
Proc Natl Acad Sci U S A. 2016;113(7):1877–82.
25. Brocato TA, Coker EN, Durfee PN, Lin YS, Townson J, Wyckoff
EF, Cristini V, Brinker CJ, Wang Z. Understanding the connection
between nanoparticle uptake and cancer treatment efficacy using
mathematical modeling. Sci Rep. 2018;8(1):7538.
26. Wang Z, Kerketta R, Chiang YL, Dogra P, Bumer JD, Brocato
TA, Day A, Xu R, Shen H, Simbawa E, al-Fluid AS, Mahmoud
SR, Curley SA, Ferrari M, Koay EJ, Cristini V. Theory and exper-
imental validation of a spatio-temporal model of chemotherapy
transport to enhance tumor cell kill. PLoS Comput Biol. 2015;11(6):
1004396.
27. Noureddine A, Butner JD, Zhu W, Naydenkov P, Peláez MJ, Goel
SC, Atomov V, Yehuda R, Wallach D, et al. Analysis of nanoparticle
delivery to tumours. Nat Rev Drug Discov. 2016;15(5):386–401.
28. Wilhelm S, Tavares AJ, Dai Q, Qutaiba M, Urolovitch TF, Chen
WCW. Analysis of nanoparticle delivery to tumours. Nat Rev
Mater. 2016;1(5):1–12.
29. Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB.
Microrna regulation of a cancer network: consequences of the feed-
back loops involving mir-17-92, c2f, and myc. PLoS One. 2015;10(7):
e1003597.
Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

73. Dogra P, Adolphi NL, Wang Z, Lin YS, Butler KS, Durfee PN, Croissant JG, Noureddine A, Coker EN, Bearer EL, Cristini V, Brinker CJ. Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics. Nat Commun. 2018;9(1):4551.

74. Dogra P, Butner JD, Nizzero S, Ruiz Ramirez J, Noureddine A, Pelaez MJ, et al. Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12(5):e1628.

75. Wang Z, Butner JD, Cristini V, Deisboeck TS. Integrated pk-pd and agent-based modeling in oncology. J Pharmacokinet Pharmacodyn. 2015;42(2):179–89.

76. Ouyang B, Poon W, Zhang YN, Lin ZP, Kingston BR, Tavares AJ, Zhang Y, Chen J, Valic MS, Syed AM, MacMillan P, Couture-Sénécal J, Zheng G, Chan WCW. The dose threshold for nanoparticle tumour delivery. Nat Mater. 2020;19(12):1362–71.

77. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25(10):1165–70.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.